高雄醫學大學圖書館 |

語系/ Language: 繁體中文

登入

回首頁

肺腺癌病人接受化療或標靶之存活及醫療資源耗用 =Survive and ...

張瓊文

肺腺癌病人接受化療或標靶之存活及醫療資源耗用 =Survive and medical resource utilization for patients with Lung adenocarcinoma undergoing chemotherapy or target therapy /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	肺腺癌病人接受化療或標靶之存活及醫療資源耗用 =/ 張瓊文
其他題名:	Survive and medical resource utilization for patients with Lung adenocarcinoma undergoing chemotherapy or target therapy /
其他題名:	Survive and medical resource utilization for patients with Lung adenocarcinoma undergoing chemotherapy or target therapy
作者:	張瓊文
出版者:	[高雄市]: [撰者], : 民110,
面頁冊數:	100葉 :圖 ; : 30公分;
附註:	指導教授: 李金德.
提要註:	研究目的肺癌是全球癌症死亡的主要原因，每年估計有180萬新病例和160萬死亡，台灣107年十大癌症死因為每十萬人口中氣管、支氣管和肺癌死亡39.8人，號稱新國病。肺腺癌病人若早期發現採取手術治療，術後給予輔助性化學治療降低復發，但肺腺癌70％確定診斷時已無法手術治療，則能選擇化療、標靶治療。研究目的，一、探討肺癌病人接受化學治療或標靶治療之存活狀態。二、探討肺癌病人接受化學治療或標靶治療之醫療費用支出。研究方法本研究的樣本取自南部某教學醫院統計處之『醫院研究資料庫』，診斷為肺癌ICD-10 C33-C34、ICD-9 162的病人，時間為2015-2018年，將其各資料串檔分析總共肺腺病人樣本數1483人，扣除資料檔案不完整者95人，實際病人樣本數1388人，使用SPSS 20.0統計軟體作為統計方法，探討肺腺癌之性別、年齡、臨床分期、吸菸與介入措施如手術、化療、標靶的存活狀態及醫療資源耗用。研究結果本研究統計分析發現年齡、BMI、腫瘤大小、臨床分期與治療模式是一重要因素會影響存活，KM存活分析一年存活率:手術治療93％，標靶治療為77％，化學治療為47％，顯示早期發現疾病早期治療是最佳機會。治療模式方面：醫療費用Scheffe以手術費用最高，第二名為手術與化療或標靶，標靶治療居第三，化療標靶第四，化學治療最後，P<.00，有顯著差異。結論與建議研究結果顯示:研究對象存活女性高於男性，平均年齡為65歲，BMI增加一個數值，死亡危害風險增加0.9倍，腫瘤大小<50mm及沒吸菸者存活狀態較佳，癌症臨床分期與癌症存活有著重大關係。治療模式：不分臨床分期以手術一年後存活期為93％，佔所有治療模式中存活狀況最佳；若以臨床分期，治療模式中以接受手術與化療或標靶，存活最久，P .00有顯著差異，顯示若能手術治療合併化療或標靶將能延長存活，所以提早發現疾病及接受手術切除治療是第一優先選擇。近年第一期肺癌病人有增加趨勢，與低劑量電腦斷層篩檢推動有關，但衛福部目前尚未將低劑量電腦斷層納入健保給付項目中，期待衛生政策的重新規劃，國人養成定期檢康檢查習慣，讓肺腺癌病人可以早期發現早期治療以提升其存活率，改善生活品質。.
電子資源:	電子資源
館藏註:	(平裝)

肺腺癌病人接受化療或標靶之存活及醫療資源耗用 =Survive and medical resource utilization for patients with Lung adenocarcinoma undergoing chemotherapy or target therapy /
張瓊文

肺腺癌病人接受化療或標靶之存活及醫療資源耗用 =Survive and medical resource utilization for patients with Lung adenocarcinoma undergoing chemotherapy or target therapy /Survive and medical resource utilization for patients with Lung adenocarcinoma undergoing chemotherapy or target therapy張瓊文 - [高雄市]: [撰者], 民110 - 100葉 :圖 ;30公分

指導教授: 李金德.

碩士論文--高雄醫學大學醫務管理暨醫療資訊學系碩士在職專班.

參考書目：葉.

目錄

研究目的肺癌是全球癌症死亡的主要原因，每年估計有180萬新病例和160萬死亡，台灣107年十大癌症死因為每十萬人口中氣管、支氣管和肺癌死亡39.8人，號稱新國病。肺腺癌病人若早期發現採取手術治療，術後給予輔助性化學治療降低復發，但肺腺癌70％確定診斷時已無法手術治療，則能選擇化療、標靶治療。研究目的，一、探討肺癌病人接受化學治療或標靶治療之存活狀態。二、探討肺癌病人接受化學治療或標靶治療之醫療費用支出。研究方法本研究的樣本取自南部某教學醫院統計處之『醫院研究資料庫』，診斷為肺癌ICD-10 C33-C34、ICD-9 162的病人，時間為2015-2018年，將其各資料串檔分析總共肺腺病人樣本數1483人，扣除資料檔案不完整者95人，實際病人樣本數1388人，使用SPSS 20.0統計軟體作為統計方法，探討肺腺癌之性別、年齡、臨床分期、吸菸與介入措施如手術、化療、標靶的存活狀態及醫療資源耗用。研究結果本研究統計分析發現年齡、BMI、腫瘤大小、臨床分期與治療模式是一重要因素會影響存活，KM存活分析一年存活率:手術治療93％，標靶治療為77％，化學治療為47％，顯示早期發現疾病早期治療是最佳機會。治療模式方面：醫療費用Scheffe以手術費用最高，第二名為手術與化療或標靶，標靶治療居第三，化療標靶第四，化學治療最後，P<.00，有顯著差異。結論與建議研究結果顯示:研究對象存活女性高於男性，平均年齡為65歲，BMI增加一個數值，死亡危害風險增加0.9倍，腫瘤大小<50mm及沒吸菸者存活狀態較佳，癌症臨床分期與癌症存活有著重大關係。治療模式：不分臨床分期以手術一年後存活期為93％，佔所有治療模式中存活狀況最佳；若以臨床分期，治療模式中以接受手術與化療或標靶，存活最久，P .00有顯著差異，顯示若能手術治療合併化療或標靶將能延長存活，所以提早發現疾病及接受手術切除治療是第一優先選擇。近年第一期肺癌病人有增加趨勢，與低劑量電腦斷層篩檢推動有關，但衛福部目前尚未將低劑量電腦斷層納入健保給付項目中，期待衛生政策的重新規劃，國人養成定期檢康檢查習慣，讓肺腺癌病人可以早期發現早期治療以提升其存活率，改善生活品質。.

(平裝)Subjects--Index Terms:

肺腺癌

肺腺癌病人接受化療或標靶之存活及醫療資源耗用 =Survive and medical resource utilization for patients with Lung adenocarcinoma undergoing chemotherapy or target therapy /
LDR:07201cam a2200229 i 4500 001 346986
008 211203s2021 ch a e m 000 0 chi d
035 $a (THES)109KMC0077D013
100 1 $a 張瓊文 $3 478568
245 1 0 $a 肺腺癌病人接受化療或標靶之存活及醫療資源耗用 = $b Survive and medical resource utilization for patients with Lung adenocarcinoma undergoing chemotherapy or target therapy / $c 張瓊文
246 1 1 $a Survive and medical resource utilization for patients with Lung adenocarcinoma undergoing chemotherapy or target therapy
260 # $a [高雄市]: $b [撰者], $c 民110
300 $a 100葉 : $b 圖 ; $c 30公分
500 $a 指導教授: 李金德.
500 $a 學年度: 109.
502 $a 碩士論文--高雄醫學大學醫務管理暨醫療資訊學系碩士在職專班.
504 $a 參考書目：葉.
505 0 # $a 目錄
520 3 $a 研究目的肺癌是全球癌症死亡的主要原因，每年估計有180萬新病例和160萬死亡，台灣107年十大癌症死因為每十萬人口中氣管、支氣管和肺癌死亡39.8人，號稱新國病。肺腺癌病人若早期發現採取手術治療，術後給予輔助性化學治療降低復發，但肺腺癌70％確定診斷時已無法手術治療，則能選擇化療、標靶治療。研究目的，一、探討肺癌病人接受化學治療或標靶治療之存活狀態。二、探討肺癌病人接受化學治療或標靶治療之醫療費用支出。研究方法本研究的樣本取自南部某教學醫院統計處之『醫院研究資料庫』，診斷為肺癌ICD-10 C33-C34、ICD-9 162的病人，時間為2015-2018年，將其各資料串檔分析總共肺腺病人樣本數1483人，扣除資料檔案不完整者95人，實際病人樣本數1388人，使用SPSS 20.0統計軟體作為統計方法，探討肺腺癌之性別、年齡、臨床分期、吸菸與介入措施如手術、化療、標靶的存活狀態及醫療資源耗用。研究結果本研究統計分析發現年齡、BMI、腫瘤大小、臨床分期與治療模式是一重要因素會影響存活，KM存活分析一年存活率:手術治療93％，標靶治療為77％，化學治療為47％，顯示早期發現疾病早期治療是最佳機會。治療模式方面：醫療費用Scheffe以手術費用最高，第二名為手術與化療或標靶，標靶治療居第三，化療標靶第四，化學治療最後，P<.00，有顯著差異。結論與建議研究結果顯示:研究對象存活女性高於男性，平均年齡為65歲，BMI增加一個數值，死亡危害風險增加0.9倍，腫瘤大小<50mm及沒吸菸者存活狀態較佳，癌症臨床分期與癌症存活有著重大關係。治療模式：不分臨床分期以手術一年後存活期為93％，佔所有治療模式中存活狀況最佳；若以臨床分期，治療模式中以接受手術與化療或標靶，存活最久，P .00有顯著差異，顯示若能手術治療合併化療或標靶將能延長存活，所以提早發現疾病及接受手術切除治療是第一優先選擇。近年第一期肺癌病人有增加趨勢，與低劑量電腦斷層篩檢推動有關，但衛福部目前尚未將低劑量電腦斷層納入健保給付項目中，期待衛生政策的重新規劃，國人養成定期檢康檢查習慣，讓肺腺癌病人可以早期發現早期治療以提升其存活率，改善生活品質。.
520 3 $a Purpose Lung cancer is the leading cause of cancer deaths worldwide, There are an estimated 1.8 million new cases and 1.6 million deaths each year。The top ten causes of cancer deaths in 107 were 39.8 trachea, bronchus and lung cancer deaths per 100,000 population, which is known as the New National Disease. If patients with lung adenocarcinoma are detected early and undergo surgery, Adjuvant chemotherapy is given after surgery to reduce recurrence, However, 70% of lung adenocarcinomas cannot be treated with surgery when the diagnosis is confirmed, so chemotherapy and targeted therapy can be chosen. Research purposes1. To explore the survival status of lung cancer patients receiving chemotherapy or targeted therapy. 2. To explore the medical expenses of lung cancer patients receiving chemotherapy or targeted therapy. Methods The samples for this study were taken from the "Hospital Research Database" of the Statistics Department of a teaching hospital in the south. Patients diagnosed with lung cancer ICD-10 C33-C34, ICD-9 162, the time is 2015-2018, Analyze the total number of samples of lung gland patients with each data string of 1483, deducting 95 people with incomplete data files, and the actual number of patient samples is 1,388. Use SPSS 20.0 statistical software as a statistical method to explore the gender, age, clinical stage, smoking and interventional measures such as surgery, chemotherapy, targeted medical resource utilization and treatment results of lung adenocarcinoma. Result The statistical analysis of this study found that age, BMI, tumor size, clinical stage and treatment mode are important factors that affect survival. KM survival analysis showed that one-year survival rate of surgical treatment 93%, targeted treatment 77%, and chemotherapy 47% .It demonstrated that early detection of disease and early treatment are the best modalities for good outcomes. In terms of treatment mode: surgical treatment has the highest medical cost, followed by surgery with chemotherapy or targeted therapy, targeted therapy only ranked third, chemotherapy targeted fourth, and finally the chemotherapy ( P<.00). Conclusion and suggestion The results of the study showed that the number of surviving women was higher than that of men. The average age was 65 years old, BMI increased by one value, the risk of death increased by 0.9 times, tumor size <50mm and non-smokers had better survival status, clinical staging of cancer and cancer survival It has a major relationship and is the main influencing factor. Treatment mode: Regardless of clinical staging, the survival time after one year of surgery is 93%, accounting for the best survival status of all treatment modes; if clinical staging is used, surgery and chemotherapy or target are accepted in the treatment mode, and the survival is the longest, P There is a significant difference in .00, which shows that if surgery is combined with chemotherapy or targeted therapy, survival will be prolonged. Therefore, early detection of the disease and surgical resection are the first priority. Recently, the number of patients with first-stage lung cancer has increased, which is related to the promotion of low-dose computer tomography screening. However, the Ministry of Health and Welfare has not yet included low-dose computed tomography in the health insurance payment program. It is looking forward to the re-planning of health policies and the habit of regular check-ups so that patients with lung adenocarcinoma can be detected and treated early to improve their survival rate and improve their quality of life ..
563 $a (平裝)
653 # # $a 肺腺癌 $a 化學治療 $a 標靶治療.
653 # # $a Lung adenocarcinoma $a chemotherapy $a target therapy.
856 7 # $u https://handle.ncl.edu.tw/11296/2afsux $z 電子資源 $2 http